Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,579 |
Reported balance
After 2026-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 10,690 · Balance 21,579 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.37 · Expires 2036-02-09 | Direct | 17,730 |
Reported balance
After 2026-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-09 · Grant · Acquired 17,730 · Balance 17,730 F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person.
F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 1,567 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.03 · Expires 2032-04-19 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.
F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 17,730 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004887 · form4.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 17,730 shares Expires 2036-02-09 F3 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004887 · form4.xml · nonDerivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,579 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerRestricted Stock Units · Derivative | 2,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · derivative · entry 6 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,951 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F6 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7 · derivative.expiration_date: Not applicable. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerStock Option (right to buy) · Derivative | 4,322 | Not disclosed Strike: $67.77 | Not disclosed |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · derivative · entry 5 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,322 shares Expires 2034-06-13 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerStock Option (right to buy) · Derivative | 7,009 | Not disclosed Strike: $63.79 | Not disclosed |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · derivative · entry 4 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,009 shares Expires 2033-06-22 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerStock Option (right to buy) · Derivative | 16,757 | Not disclosed Strike: $55.48 | Not disclosed |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · derivative · entry 3 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,757 shares Expires 2032-06-08 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $60.03 | Not disclosed |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-04-19 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Disposition to issuerCommon Stock | 1,567 | $132.00 | $206,844.00 |
DisclosureSEC source: 0000950170-25-049830 · ownership.xml · nonDerivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2 · kind: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2 · price: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 16,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005539 · form4.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,279 Underlying: Common Stock · 16,279 shares Expires 2035-02-19 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005539 · form4.xml · nonDerivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,889 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Comprised of, as of the transaction date, 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1). Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 16:15 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 20,011 | $0.00 Strike: $17.49 | $0.00 |
DisclosureSEC source: 0001140361-25-000079 · form4.xml · derivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,011 Underlying: Common Stock · 20,011 shares Expires 2034-12-30 F1 · derivative.exercise_date: The options were granted to the reporting person on 12/30/2024 upon joining the ADMA Biologics, Inc. Board of Directors and will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| June 23, 2024 Filed Jun 25, 2024 18:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077470 · ownership.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024). F2 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024). Read SEC document |
| June 23, 2024 Filed Jun 25, 2024 18:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 1,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-077470 · ownership.xml · nonDerivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 18:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 4,322 | $0.00 Strike: $67.77 | $0.00 |
DisclosureSEC source: 0000950170-24-075082 · ownership.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,322 Underlying: Common Stock · 4,322 shares Expires 2034-06-13 Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 18:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 2,951 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075082 · ownership.xml · derivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,951 Underlying: Common Stock · 2,951 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025). F2 · derivative.expiration_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025). Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 7,009 | $0.00 Strike: $63.79 | $0.00 |
DisclosureSEC source: 0001209191-23-039929 · doc4.xml · derivative · entry 2 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,009 Underlying: Common Stock · 7,009 shares Expires 2033-06-22 Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039929 · doc4.xml · derivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,567 Underlying: Common Stock · 1,567 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024). F2 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024). Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:03 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 16,757 | $0.00 Strike: $55.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036375 · doc4.xml · derivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,757 Underlying: Common Stock · 16,757 shares Expires 2032-06-08 Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 16:54 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001209191-22-025186 · doc4.xml · derivative · entry 1 Salas Eduardo Rene · CIK 0001924188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-04-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.